|Calculated MW||This protein is fused with 6×his tag at C-terminus, has a calculated MW of 67 kDa expressed. The predicted N-terminus is Met1. Protein migrates as the predominant 64 kDa form and a less-frequent 24-kDa form in reduced SDS-PAGE resulting from alternative splicing.|
|Other Names||GAD1, CPSQ1, GAD, SCP, GAD-1, CPSQ-1, GAD67, GAD-67|
|Source||HEK 293 cells|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4, 1 mM EDTA with some stabilizer. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Glutamate decarboxylase 1 (GAD1), also known as 67 kDa glutamic acid decarboxylase and Glutamate decarboxylase 67 kDa isoform, is a member of the group II decarboxylase family. GAD1 is expressed in benign and malignant prostatic tissue and may serve as a highly prostate-specific tissue biomarker. GAD1 is responsible for catalyzing the production of gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been identified in the human pancreas since it has been identified as an autoantigen and an autoreactive T cell target in insulin-dependent diabetes. GAD1 may also play a role in the stiff man syndrome. Defects in GAD1 are the cause of cerebral palsy spastic quadriplegic type 1 (CPSQ1) which is a non-progressive disorder of movement and/or posture resulting from defects in the developing central nervous system. GAD1 has been shown to interact with GAD2. Affected individuals manifest symmetrical, non-progressive spasticity and no adverse perinatal history or obvious underlying alternative diagnosis.
Bu D.-F.,et al.Proc. Natl. Acad. Sci. U.S.A. 89:2115-2119(1992).
Bu D.-F.,et al.Genomics 21:222-228(1994).
Kelly C.D.,et al.Lancet 338:1468-1469(1991).
Kelly C.D.,et al.Ann. Hum. Genet. 56:255-265(1992).
Yamashita K.,et al.Biochem. Biophys. Res. Commun. 192:1347-1352(1993).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.